(1)$双鹭药业(SZ002038)$ 来那度胺(立生)晶型与$新基制药(CELG)$ 来那度胺(瑞复美)晶型不同,可以挑战新基专利。
(2) 180天市场独占期的两个条件:①最早提交ANDA(First to file),可以是多家企业 ②Para IV声明。
查看全文
医药魔方2018-06-29 09:37
康朴生物医药技术(上海)有限公司(康朴生物医药)于2018年6月27日宣布,该公司独立开发的具有全球自主知识产权的I类创新药KPG-121联合恩杂鲁胺(Enzalutamide)治疗转移性去势抵抗性前列腺癌(mCRPC)的I期临床试验已经在美国展开。
此项多中心、开放性的临床研究旨在评价KPG-121的安全性、...查看全文
张小丰2018-06-29 08:24
$Acceleron Pharma Inc. (XLRN)$ $新基制药(CELG)$
Luspatercept 细节还未公布,但是主要终点和次要终点都成功了。 这个对于新基是不能失败的项目,因为之前已经失败1个,另外一个很悲催的RTF。。。查看全文
现在投机而立家2018-06-29 06:27
$新基制药(CELG)$ 恭喜大家~
Celgene (CELG), Acceleron (XLRN) Report Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study查看全文
牛氓的胜利2018-06-21 14:59
$双鹭药业(SZ002038)$来那度胺和$新基制药(CELG)$来那度胺同属于全球规范市场,享有同等核心专利保护到2024年。印度也有药品专利法,印度提前仿制药品只在不规范市场销售,不可能进入中国市场。查看全文
$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792 Size: 69 KB 网页链接
$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796 Size: 42 KB 网页链接
$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527 Act: 34 Size: 15 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217 Act: 33 Size: 39 KB 网页链接